EUVIMEDEUVIMED entdecken
Open Access

Chemical remodeling of a cellular chaperone to target the active state of mutant KRAS

Christopher J Schulze iD, Kyle J Seamon iD, Yulei Zhao iD, Yu C Yang iD, Jim Cregg, Dongsung Kim iD, Aidan Tomlinson iD, Tiffany J Choy iD, Zhican Wang, Ben Sang iD, Yasin Pourfarjam, Jessica Lucas iD und 24 weitere

Science · 18.08.2023 · 381 (6659) · 794-799

DOI: 10.1126/science.adg9652 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science, erschienen am 18.08.2023. Verfasst von Christopher J Schulze und 35 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biology, Revolution Medicines, Inc., Redwood City, CA 94063, USA. Hauptthemen laut MEDLINE: Biological Products, Molecular Chaperones, Proto-Oncogene Proteins p21(ras), Cyclophilin A. Die Arbeit wurde bisher 280-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The discovery of small-molecule inhibitors requires suitable binding pockets on protein surfaces. Proteins that lack this feature are considered undruggable and require innovative strategies for therapeutic targeting. KRAS is the most frequently activated oncogene in cancer, and the active state of mutant KRAS is such a recalcitrant target. We designed a natural product–inspired small molecule that remodels the surface of cyclophilin A (CYPA) to create a neomorphic interface with high affinity and selectivity for the active state of KRAS G12C (in which glycine-12 is mutated to cysteine). The resulting CYPA:drug:KRAS G12C tricomplex inactivated oncogenic signaling and led to tumor regressions in multiple human cancer models. This inhibitory strategy can be used to target additional KRAS mutants and other undruggable cancer drivers. Tricomplex inhibitors that selectively target active KRAS G12C or multiple RAS mutants are in clinical trials now (NCT05462717 and NCT05379985).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biological ProductsMolecular ChaperonesProto-Oncogene Proteins p21(ras)Cyclophilin AImmunophilinsNeoplasmsHumansCysteineSignal Transduction

Substanzen

Biological ProductsCysteineKRAS protein, humanMolecular ChaperonesProto-Oncogene Proteins p21(ras)Cyclophilin AImmunophilins

Autor:innen und Institutionen

  • Department of Biology, Revolution Medicines, Inc., Redwood City, CA 94063, USA.
  • Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer, New York, NY 10065, USA.
  • Department of Discovery Chemistry, Revolution Medicines, Inc., Redwood City, CA 94063, USA.
  • Department of Non-clinical Development and Clinical Pharmacology, Revolution Medicines, Inc., Redwood City, CA 94063, USA.
  • Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Department of Medicine, Weill Cornell Medical College, New York, NY 10065, USA.

ORCID-Profile: Christopher J Schulze, Kyle J Seamon, Yulei Zhao, Yu C Yang, Dongsung Kim, Aidan Tomlinson, Tiffany J Choy, Ben Sang, Jessica Lucas, Antonio Cuevas-Navarro, Carlos Ayala-Santos, Alberto Vides, Chuanchuan Li, Abby Marquez, Mengqi Zhong, Vidyasiri Vemulapalli, Anthony Salvador, Anthony Milin, Anqi Chen, Elena S Koltun, Jacqueline A M Smith, Piro Lito

Förderung

  • NCI NIH HHS

Zitieren

APA

Schulze, C. J., Seamon, K. J., Zhao, Y., Yang, Y. C., Cregg, J., Kim, D., Tomlinson, A., Choy, T. J., Wang, Z., Sang, B., Pourfarjam, Y., Lucas, J., Cuevas-Navarro, A., Ayala-Santos, C., Vides, A., Li, C., Marquez, A., Zhong, M., Vemulapalli, V., …, & Lito, P. (2023). Chemical remodeling of a cellular chaperone to target the active state of mutant KRAS. Science, 381(6659), 794-799. https://doi.org/10.1126/science.adg9652

Vancouver

Schulze CJ, Seamon KJ, Zhao Y, Yang YC, Cregg J, Kim D, et al. Chemical remodeling of a cellular chaperone to target the active state of mutant KRAS. Science. 2023;381(6659):794-799. doi:10.1126/science.adg9652

BibTeX
@article{Schulze2023,
  author = {Schulze, Christopher J and Seamon, Kyle J and Zhao, Yulei and Yang, Yu C and Cregg, Jim and Kim, Dongsung and Tomlinson, Aidan and Choy, Tiffany J and Wang, Zhican and Sang, Ben and Pourfarjam, Yasin and Lucas, Jessica and Cuevas-Navarro, Antonio and Ayala-Santos, Carlos and Vides, Alberto and Li, Chuanchuan and Marquez, Abby and Zhong, Mengqi and Vemulapalli, Vidyasiri and Weller, Caroline and Gould, Andrea and Whalen, Daniel M and Salvador, Anthony and Milin, Anthony and Saldajeno-Concar, Mae and Dinglasan, Nuntana and Chen, Anqi and Evans, Jim and Knox, John E and Koltun, Elena S and Singh, Mallika and Nichols, Robert and Wildes, David and Gill, Adrian L and Smith, Jacqueline A M and Lito, Piro},
  title = {Chemical remodeling of a cellular chaperone to target the active state of mutant KRAS},
  journal = {Science},
  year = {2023},
  volume = {381},
  number = {6659},
  pages = {794--799},
  doi = {10.1126/science.adg9652}
}
Kostenlos starten →